Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

723
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
723
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

8.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Cancer Vaccines01:30

Cancer Vaccines

554
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
554
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

75.2K
Overview
75.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel anatomical approach to central lymphatics: Cadaveric validation of abdominal and thoracic access for lymphovenous anastomosis.

Current problems in surgery·2026
Same author

Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort.

JHEP reports : innovation in hepatology·2026
Same author

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.

Nature·2026
Same author

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).

Future oncology (London, England)·2026
Same author

Medusa Head Aspect of the Thoracic Duct in CCLA Patients: Anatomical Variation or Pathological Marker? A Multicenter Case-Control Study.

Clinical anatomy (New York, N.Y.)·2026
Same author

Invasive aspergillosis in liver transplant recipients in France (2007-21): a nationwide, retrospective, matched case-control study.

The Lancet. Microbe·2026

Related Experiment Video

Updated: Oct 9, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K

Immunomodulation for hepatocellular carcinoma therapy: current challenges.

Zuzana Macek Jilkova1,2,3, Julien Ghelfi1,2,4, Thomas Decaens1,2,3

  • 1Université Grenoble Alpes, Grenoble.

Current Opinion in Oncology
|December 19, 2021
PubMed
Summary

Immune-checkpoint inhibitors show limited response in hepatocellular carcinoma (HCC). Combining these therapies with locoregional treatments may improve outcomes by modulating the tumor immune microenvironment.

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

331
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.5K

Related Experiment Videos

Last Updated: Oct 9, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

331
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.5K

Area of Science:

  • Oncology
  • Immunotherapy
  • Hepatocellular Carcinoma Research

Background:

  • Novel immunotherapies, including immune-checkpoint inhibitors, have transformed cancer treatment.
  • Response rates to immune-checkpoint inhibitors in hepatocellular carcinoma (HCC) patients are currently low.
  • Understanding predictive factors and immunomodulation is crucial for improving HCC immunotherapy efficacy.

Purpose of the Study:

  • To provide an update on immune-checkpoint inhibitor therapy in HCC.
  • To focus on predictive factors influencing immunotherapy response.
  • To explore the role of locoregional therapies in modulating the immune response for HCC.

Main Methods:

  • Review of recent findings in HCC immunotherapy.
  • Analysis of predictive markers for treatment response.
  • Investigation of immunomodulatory effects of locoregional therapies.

Main Results:

  • The immune contexture of HCC is a key predictive marker for immunotherapy response.
  • The etiology of HCC (e.g., NASH vs. viral) influences immunotherapy efficacy.
  • Locoregional therapies, such as percutaneous ablations and transarterial therapies (TACE, SIRT), induce beneficial intratumoral and systemic immune changes.
  • Combining locoregional therapies with immune-checkpoint inhibitors may convert "cold" tumors to "hot" tumors, improving outcomes.

Conclusions:

  • Future HCC management requires patient stratification based on HCC signature and etiology.
  • Combined approaches utilizing locoregional therapies alongside immunotherapies are pivotal for enhancing treatment outcomes.
  • Personalized treatment strategies integrating predictive markers and locoregional interventions are essential for advancing HCC care.